Novartis released results from the Phase III CANOPY-A trial on Monday showing that canakinumab (ACZ885) failed to meet the primary efficacy endpoint in adult non-small cell lung cancer (NSCLC) patients. It's the latest miss for the highly-studied drug.
Adding Ilaris, or canakinumab, to Merck’s Keytruda and platinum-based chemotherapy couldn’t extend the lives of newly diagnosed NSCLC patients, Novartis said Monday. The experimental regimen also failed to show a benefit in slowing tumor progression over the standard immunotherapy-chemo combo.
XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the Company’s Board of Directors. Ms. Franklin has significant experience in corporate development and strategy, including over 10 years of experience founding and leading Blaze and 10 years of business development experience prior to that at ZymoGenetics.
Novartis' plans to repurpose a rare disease drug as a lung cancer treatment have yet to bear fruit, with the Swiss drugmaker reporting Monday that the therapy failed to meet its goal in a second Phase 3 study.
Basel, October 25, 2021 — Novartis announced today that the CANOPY-1 Phase III study did not demonstrate the statistically significant primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients treated with canakinumab (ACZ885) combined with pembrolizumab plus platinum-based doublet
ZURICH (Reuters) - Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a Phase III study, but other late-stage trials are ongoing.
Novartis announced the phase III CANOPY-2 study evaluating canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1ß), in combination with the chemotherapy agent docetaxel, did not meet its primary endpoint of overall survival (OS). The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L) inhibitor immunotherapy. Two phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings. Novartis and CANOPY-2 investigators will analyze the study data and are expected to submit its findings for presentation at an upcoming medical meeting.
Novartis has revealed that its arthritis drug, theinterleukin-1 beta inhibitor canakinumab, in combination with standard of care (SoC), failed to meet its main goal in the treatment of hospitalised patients with COVID-19 pneumonia and cytokine release syndrome (CRS).
Novartis announced new data from an interim analysis for the randomized, double-blind, placebo-controlled CAN-COVID trial evaluating the efficacy and safety of canakinumab in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS). The ongoing trial failed to meet its primary endpoint showing that treatment with canakinumab plus standard of care (SoC) did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus SoC up to Day 29. The trial did not meet its key secondary endpoint of reducing the COVID-19-related death rate during the 4-week period after treatment. The safety profiles of canakinumab plus SoC and placebo plus SoC were comparable.
Novartis Pharms's Biological Canakinumab Receives Approval In US